Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03453307|
Recruitment Status : Recruiting
First Posted : March 5, 2018
Last Update Posted : March 5, 2018
|Condition or disease|
Methods - Open label single arm observatory comparison experiment
- Enrolled patients (before or after surgery) were treated with chemotherapy or target therapy. The medication regime and treatment cycle were decided based on the clinical guideline and evidence-based medicine. This clinical study will not affect the treatment plan of the patients.
- The resection tissue or biopsy tissue of NSCLC will be collected, and subject to ex vivo 3-D culture to establish patient-derived tumor organoid models, which will be used for drug sensitivity test.
- The patient-derived organoid-based drug sensitivity test will be compared with clinical treatment data of chemotherapy or target therapy, followed by correlation analysis.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||The Correlation Study of the Drug Sensitivity Between Ex Vivo Model of Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Organoids and Clinical Response in NSCLC Patients|
|Actual Study Start Date :||January 30, 2018|
|Estimated Primary Completion Date :||July 30, 2020|
|Estimated Study Completion Date :||July 30, 2021|
NSCLC patients receiving chemotherapy or target therapy treatment.
- Correlation of ex vivo sensitivity test on patient derived organoid models [ Time Frame: 12 months ]The drug sensitivity was tested on patient-derived tumor organoids, which is compared with clinical response of the chemo or target therapy treatment.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03453307
|Contact: Zhijian Sun, Dr.||(86) firstname.lastname@example.org|
|Contact: Chenggang Zhu, Dr.||(86) email@example.com|
|People's Hospital of Hebei Province||Recruiting|
|Shijiazhuang, Hebei, China, 050051|
|Contact: Lijun Liu 18903391188 firstname.lastname@example.org|
|Principal Investigator:||Zhijian Sun, Dr.||K2 Oncology, Inc.|